We previously suggested that insulin increases diacylglycerol (DAG) in BC3H-1 myocytes, both by increases in synthesis de novo of phosphatidic acid (PA) and by hydrolysis of non-inositol-containing phospholipids, such as phosphatidylcholine (PC) and phosphatidylethanolamine (PE) 
INTRODUCTION
amino acid transport and/or pyruvate dehydrogenase activity in the BC3H-1 myocyte [8] and rat adipose [9, 10] Insulin is known to increase the synthesis of phosphaand cardiac [11] tissues. More recently, we have reported tidic acid (PA), inositol phospholipids and other that insulin increases [3H]glycerol incorporation into PA phospholipids in BC3H-1 myocytes [1, 2] and rat adipose within seconds, and this PA is primarily converted tissue [2] [3] [4] . This increase in general phospholipid directly into DAG and phosphatidylcholine (PC) and synthesis occurs rapidly and is associated with increases phosphatidylethanolamine (PE) [5] . To explain conin diacylglycerol (DAG) [1, 2, 5] and cytosolic and current increases in PI content, we have also postulated membrane-bound protein kinase C activity [6, 7] . that insulin increases DAG and PA by stimulating the over, activation of the DAG-protein kinase C signalling hydrolysis of PC or other lipids in BC3H-1 myocytes. In system is associated with increases in glucose transport, the present paper, we present further evidence that
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insulin increases DAG by two mechanisms, i.e. synthesis de novo of PA, DAG and PC, and hydrolysis of preformed lipids; we also examined several potential mechanisms and metabolic requirements for these effects of insulin. EXPERIMENTAL BC3H-1 myocytes were cultured for 10 days to confluence, cellular maturity and maximal responsiveness to insulin as described previously [1, 2, 5] . On the day of the experiment, Dulbecco's Modified Eagle's Medium containing 20 % fetal-calf serum was removed and replaced with Dulbecco's Phosphate-Buffered Saline (DPBSGA) containing 0.1 mM-CaCl2, 5.6 mM-glucose and 1 mg of bovine serum albumin/ml (see [1, 2] ), unless indicated otherwise. In most experiments, cells were grown on 35 mm-diam. plates (0.5 mg of cellular protein) and 1 or 2 ml of DPBSGA buffer was used during the experimental period. In some experiments, the cells were grown on 60 mm or 100 mm-diam. plates, and 3 or 5 ml, respectively, of DPBSGA buffer was used. As specified in the text, the cells were incubated with [2-3H] glycerol for 2 h or 3-10 days in the absence of treatments, and then insulin or other treatments were added and reactions were followed for various periods (1-30 min). In some experiments, [ [5,6,7,11,12,14,15- Glycerol 3-phosphate labelling and mass were determined as follows. After incubation, media were removed by aspiration and cells were extracted with chloroform/ methanol/water (3:1:1, by vol.). After vortex-mixing and centrifugation, aqueous phases were removed and samples were chromatographed on Dowex-1 columns (0.5 cm x 2 cm; formate form, Bio-Rad). Free glycerol and glycerol 3-phosphate were quantitatively eluted with water and 0.2 M-ammonium formate/0.1 M-formic acid respectively (see [13] ). It should be noted that [3H]-glycerol labelled in the 2-position cannot be converted into dihydroxyacetone phosphate or other glycolytic intermediates without loss of radioactivity. Thus all radioactivity in the aqueous glycerol 3-phosphate column fraction can only be attributed to this substance. This conclusion is supported by the fact that aqueous extracts from cells labelled with [2-3H] glycerol for 2 h or 3 days yielded only a single peak of radioactivity (in addition to free glycerol, which did not bind to the column) during elution of the columns with a linear ammonium formate gradient in 0.1 M-formic acid, and the elution pattern was identical with that of [U-14C]-glycerol 3-phosphate standard. The mass of glycerol 3-phosphate in the column fraction was determined by spectrophotometric determination of the NADH generated after addition of glycerol-3-phosphate dehydrogenase, NAD+, glycine buffer (pH 9.6) and hydrazine as a trapping agent [14] .
DAG mass in lipid extracts was determined by the method of Preiss et al. [15] (Figs. 1 and 2 ).. Thereafter, the rate of total glycerolipid labelling (Table 1) and other phospholipids such as PA and PI (see [5] ). Insulininduced increases in [3H]glycerol labelling of both DAG and total glycerolipids correlated well temporally with increases in DAG mass, which was measured simultaneously in the same lipid extracts (Fig. 2 ).
In contrast with increases in [3H]glycerol incorporation into PA, DAG and other neutral lipids and phospholipids, [3H]glycerol incorporation into glycerol 3-phosphate, the precursor for PA and all subsequently synthesized glycerolipids, was decreased by insulin treatment (Figs. 1, 2 and 5), probably reflecting increased utilization of glycerol 3-phosphate for PA synthesis. These results rule out the possibility that insulin effects on [3H]glycerol incorporation into glycerolipids are due to an increase in glycerokinase activity, or other factors which may result in an increase of the labelling of glycerol 3-phosphate, e.g. a decrease in glycerol-3-phosphate dehydrogenase activity.
As shown in Table 2 , tissue concentrations of glycerol 3-phosphate in control and 1 min-insulin-treated myocytes were 0.34 and 0.38 mm respectively. Also, the specific radioactivity of total glycerol 3-phosphate was unchanged by 1 min of insulin treatment. Although not examined here (since insulin effects were usually maximal at 1 min), longer times of insulin treatment would be expected to increase glucose uptake, glycolytic flux and amounts of unlabelled glycerol 3-phosphate [13] .
The above results indicated that insulin abruptly increased the net rate of synthesis de novo of PA and total glycerolipid. Since the control rate of [3H]glycerol labelling of total glycerolipids was relatively constant during the 150 min experimental period, it was possible to calculate this rate (or velocity) as c.p.m. incorporated into total glycerolipids/min of incubation. In a series of eight separate experiments, the control rate of labelling (i.e. the resultant of synthesis and degradation) was determined and compared with that observed during the first 1 min of treatment with 200 nM-insulin: thus the net rate of total glycerolipid labelling increased approx. 60-fold (from 167+47 to 10893+3428 c.p.m./min; mean +S.E.M.) during this 1 min treatment period (also see Fig. 3 ).
The effect of insulin on total glycerolipid labelling was maximal at insulin concentrations of 20-200 nm, and half-maximal at approx. 2 nm (Fig. 3 ). These doses of insulin are comparable with those previously reported to provoke maximal and half-maximal increases in glucose transport [16] .
In (Fig. 7) . Over the next 1 min the amount of labelled PC/PE decreased to baseline, only to increase again during the next several minutes.
We have reported that insulin provokes a small transient increase in inositol-phospholipid hydrolysis in rat adipose tissue [19] , but apparently not in BC3H-1 myocytes [2] . Insulin is also known to increase the hydrolysis of a PI-glycan by a specific phospholipase C [12, 18] , and we have suggested that insulin may activate a phospholipase C which hydrolyses lipids such as PC/ PE [5] . We therefore questioned whether the increase in PA-DAG synthesis de novo observed during insulin action may be triggered by increases in phospholipase C activity, Ca2l mobilization, DAG generation from sources other than newly synthesized PA, and/or protein kinase C activation. To evaluate these possibilities, we used phenylephrine {which increases inositol-phospholipid hydrolysis, inositol phosphates, cytosolic Ca2" and protein kinase C activity [20, 21] but this was associated with a decrease in labelled phospholipids (chiefly PC) and, moreover, total glycerolipid labelling (the sum of phospholipids, DAG, TAG and MAG), and, therefore, presumably PA-DAG synthesis de novo, was not increased.
DISCUSSION
The present findings provide further evidence that insulin rapidly increases DAG in BC3H-1 myocytes by stimulating both synthesis de novo of PA and hydrolysis of pre-existing phospholipids. With respect to the mechanism of PA synthesis de novo, insulin, if anything, provoked decreases in glycerol 3-phosphate labelling, and increases in [3H]glycerol incorporation into PA, DAG, PC and other glycerolipids cannot be explained by an increase in the labelling or specific radioactivity of glycerol 3-phosphate. Further evidence that increased incorporation of [3H]glycerol into glycerolipids reflects increased PA synthesis de novo is provided by the following: (a) insulin also increased ["4C]glucose incorporation into glycerolipids at early time points, when insulin effects on glucose transport would not be expected [16] suggesting that PC/PE synthesis itself is stimulated; (d) increases in lipid labelling were observed regardless of whether insulin and [3H]glycerol were added simultaneously, or whether insulin was added to cells which had been prelabelled for 2 h or 3 or 10 days; and (e) in all labelling protocols, total glycerolipid labelling was increased.
The present and previous [5] findings indicate that increases in synthesis de novo of PA, DAG and PC/PE occur within seconds of addition of insulin to BC3H-l myocytes. The effect on this synthesis seems to be biphasic, with a nadir at 1-5 min, followed by a secondary increase. For PC/PE labelling, it is at present uncertain how much of this nadir reflects a transient decrease in PC/PE synthesis, or an increase in PC/PE hydrolysis. With respect to the latter possibility, previous data [5] from 2 h glycerol-labelling experiments had indirectly suggested the existence of concurrent hydrolysis of noninositol phospholipids, as there was no other reasonable explanation for increases in PI mass, which were observed at times when [3H]glycerol incorporation into PI was not commensurately increased. The present findings provide further evidence for existence of a hydrolytic component in that: (a) persistent and commensurate increases in [3H]glycerol labelling of PI were observed, but only in experiments in which cellular phospholipids were extensively prelabelled for 3-10 days, before insulin treatment; and (b) on the basis of the specific radioactivity of glycerol 3-phosphate, the pathway of PA-DAG-PC synthesis de novo could account for no more than 15-30 Qo of the observed increases in DAG content.
The present findings illustrate some of the difficulties encountered in trying to estimate the relative contributions of PA synthesis de novo and phospholipid hydrolysis to observed increases in either the [3H]glycerol labelling or content of DAG during insulin action. Although there were reasonably good correlations between time-related increases in mass and [3H]glycerol labelling of DAG in 2 h, 3-day and 10-day prelabelling experiments, this may reflect either stimulation of the pathway of PA synthesis de novo or hydrolysis of preexisting phospholipids, or both, since, as shown above, (a) the glycerol 3-phosphate pool may be heavily labelled even after 10 days of prelabelling (in fact, we have not been successful in attempts to deplete radioactivity in this pool sufficiently in prolonged 'chase' experiments), and (b) [3H]glycerol-labelled PC/PE may also provide substrate for phospholipase C even in 2 h prelabelling experiments. Nevertheless, increased early labelling of PA and DAG in experiments in which insulin was added simultaneously with [3H]glycerol, and increases in PC and total glycerolipid labelling, coupled with knowledge of the fact that most newly synthesized PA is directly converted into DAG and thence into PC, make it abundantly clear that PA synthesis de novo must contribute substantially to, and phospholipid hydrolysis cannot be the sole mechanism for, insulin-induced increases in DAG. Similarily, the estimation of the contribution of PA synthesis de novo (based on glycerol 3-phosphate specific radioactivity), indicates that hydrolysis of pre-existing phospholipids must also contribute significantly.
We have now evaluated several possible mechanisms whereby insulin may activate PA-DAG synthesis de novo. Clearly, hydrolysis of inositol phospholipids (as provoked by phenylephrine), Ca2" mobilization and Vol. 256 protein kinase C activation do not appear to be responsible for initiating the insulin effect on glycerolipid synthesis de novo. Similarly, non-specific hydrolysis of phospholipids such as PC/PE can not explain the insulin effect on the 'de novo' pathway. Other mechanisms that need to be evaluated include fatty acyl-CoA availability and stimulation of glycerol-3-phosphate acyltransferase activity by PI-glycan head groups (see [22] ).
In summary, our previous [1, 2, 5] and present findings in BC3H-1 myocytes suggest that there are at least two mechanisms for increasing DAG during insulin action, i.e. PA-DAG-PC/PE synthesis de novo and phospholipid hydrolysis. With respect to the latter, DAG may be increased by hydrolysis of the PI-glycan, but it is difficult to determine how much DAG is derived from this source, since, as shown here, myristate labelling of DAG is not specific and may derive from hydrolysis of PC as well as the PI-glycan. Increases in PI synthesis may result from increases in PA, derived either from 'true' synthesis de novo from glycerol 3-phosphate and fatty acyl-CoA, or from hydrolysis of phospholipids by phospholipase C or D. The metabolic consequences of increases in DAG by these mechanisms remain to be determined, but protein kinase C activation seems to occur [6, 23, 24] .
